Welcome to Storyflo Daily Biotech. I'm Bea.
The platform-tech grant worth your watchlist: per Genetic Engineering News, a University of Bath–led team received £500,000 to develop GlucoBrain, an organ-on-chip device that replicates connections between the brain, gut, and pancreas. GEN reports collaborators include investigators from Oxford and Johns Hopkins, with project lead Despina Moschou framing the device as a way to study, in real time, how signals travel between organs and why glucose levels are linked to cognitive decline. The three-year project starts in October. The structural read: most current diabetes-dementia mechanism work depends on animal models or single-tissue cell culture, and a connected multi-organ chip is the credible bridge to drug-screening relevance.
The neuroscience target the field will be debating: per Genetic Engineering News, UCLA Health researchers led by Carlos Portera-Cailliau identified the synaptic protein EPAC2 as a potential therapeutic target for Fragile X syndrome. GEN reports the paper, published in Neuron, showed that blocking EPAC2 in Fragile X model mice restored abnormal brain-activity patterns and improved several FXS-associated behavioral symptoms. GEN notes Fragile X affects roughly one in 2,000 boys and is the most common genetic cause of intellectual disability and autism, with prior clinical trials since the 1991 FMR1 discovery having failed to produce an approved therapy. EPAC2 is the most concrete new mechanism the field has had in years.
The MS methodology paper to log: per Genetic Engineering News, a Nature Communications paper from Katrina Adams at Notre Dame did a comparative transcriptomic analysis of two mouse demyelination models — cuprizone and lysophosphatidylcholine — and benchmarked them against human MS lesion tissue. GEN's read: CPZ is better for studying myelin-producing cells under stress because the loss is gradual, while LPC is better for studying immune response because the lesion forms in days. The implication: choosing the wrong model has been a quiet source of late-stage MS trial failure.
The biotech tape worth the time-stamp: per Genetic Engineering News, Regenxbio shares fell 43% over two days last week to a 52-week low despite positive pivotal Phase III data for its Duchenne muscular dystrophy gene-therapy candidate RGX-202. GEN reports the selloff was driven by Regenxbio's disclosure that the FDA had recommended a randomized controlled trial — a signal investors read as pushing potential market entry from 2027 out to 2030 or later. The structural read: gene-therapy investors are now pricing FDA-flexibility signals more than efficacy data, and that's a meaningful regime change.
And upstream: per Genetic Engineering News, an Axio BioPharma–Ansa Biotechnologies webinar will benchmark codon-optimization strategies, with GEN previewing data that AI-codon-optimized constructs showed consistently higher transient antibody expression in matched CHO and HEK293 conditions.
That's your Storyflo Daily Biotech. Sources in the notes. Bea out.
